贝那普利联合黄葵胶囊治疗慢性肾小球肾炎的有效性和安全性

Efficacy and safety of benazepril combined with Huangkui capsule in the treatment of chronic glomerulonephritis

目的分析贝那普利联合黄葵胶囊治疗慢性肾小球肾炎的有效性和安全性。方法选择本院2016年7月~2019年7月收治的慢性肾小球肾炎患者110例,按随机数字表法分为两组,对照组55例采用贝那普利治疗,研究组55例在对照组基础上加入黄葵胶囊治疗,对两组临床疗效及不良反应情况比较。结果对照组患者临床总有效率为78.18%,比研究组的92.73%低(P<0.05);研究组尿素氮为(5.16±0.55)mmol/L、血肌酐为(71.78±5.23)μmol/L、24h尿蛋白定量为(0.53±0.39)g、总胆固醇为(6.25±0.33)mmol/L及三酰甘油为(1.52±0.35)mmol/L,各指标均比对照组低(P<0.05);研究组腹泻、头晕等不良反应率为5.45%,比对照组的18.18%低(P<0.05)。结论贝那普利联合黄葵胶囊治疗慢性肾小球肾炎患者,不但能改善患者相关指标,而且能减少不良反应发生,安全性高,临床上值得推广使用。

Objective To analyze the efficacy and safety of benazepril combined with Huangkui in the treatment of chronic glomerulonephritis.Methods The clinical data of 110 patients with chronic glomerulonephritis admitted to our hospital from July 2016 to July 2019 were selected as the research objects and divided into the study group(n=55)and the control group(n=55)according to the random number table method.The control group was treated with benazepril,while the study group was additionally treated with Huangkui capsule on the basis of the control group.The clinical efficacy and adverse reactions of the two groups were compared.Results The total effective rate of 78.18%in the control group was lower than 92.73%in the study group(P<0.05).The levels of urea nitrogen(5.16±0.55)mmol/L,serum creatinine(71.78±5.23)μmol/L,24-hour urine protein(0.53±0.39)g,total cholesterol(6.25±0.33)mmol/L and triacylglycerol(1.52±0.35)mmol/L in the study group were lower than those in the control group(P<0.05).The incidence of adverse reactions such as diarrhea and dizziness in the study group was 5.45%,lower than 18.18%in the control group(P<0.05).Conclusion Benazepril combined with Huangkui in the treatment of patients with chronic glomerulonephritis can not only improve the relevant indicators of the patient,but also reduce the occurrence of adverse reactions.It has high safety and is worthy of promotion in the clinic.